Article
An insertion mutation of ERBB2 enhances breast cancer cell growth and confers resistance to lapatinib through AKT signaling pathway.
Biology open - 24 Jan 2020
Yang Zi-Yan, Yang Liu, Xu Chun-Wei, Wang Xiao-Jia, Lei Lei
Abstract excerpt
In clinical practice, some breast cancer (BC) patients carry a rare ERBB2 in-frame insertion (p. Pro780_Tyr781insGlySerPro) and are resistant to anti-ERBB2 therapy. To explore the potential procarcinogenic role of this ERBB2 mutation, we conducted the present study using BC cells overexpressing wild-type (WT) ERBB2 or P780-Y781 ERBB2 [mutated (MT)]. MDA-MB-231 and MCF-7 cells were transfected with the following...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.